In unadjusted analyses, the prevalence of a family history of autoimmune disease was significantly higher among children with MS compared with their healthy peers (68.1% vs 49.5%). This finding "reinforces the fact that there are probably overlapping genetic risk factors for autoimmunity in general, but the specific autoimmune disease a person gets is based on exposures over time," lead author Benjamin M. Rates of those diseases, including ones affecting the thyroid, were higher among families with individuals who had pediatric MS.
The risk for discontinuing interferons was higher among patients with depression vs without.Ī separate study examined the relationship between pediatric MS and other autoimmune disorders. The median time between disease-modifying therapy start and discontinuation was 1.81 years.
The study included nearly 4000 patients from the Swedish MS Registry. New research found that patients who used rituximab off-label to treat RRMS had a 28% lower risk for depression than those who used interferons. The lifetime prevalence of depression in this group is approximately 50%. The choice of treatment in patients with MS may be even more significant than first thought. Study author Matilde Inglese, MD, PhD, stated, "The best patient candidates for this procedure are those with highly active multiple sclerosis who are not responsive to high-efficacy drugs such as alemtuzumab or ocrelizumab." Among patients with progressive MS, 71% had no worsening of disability at 5 years, and 57.2% at 10 years. Patients with relapsing-remitting MS (RRMS) had better results than those with other forms, with 85.5% experiencing no worsening of disability at 5 years, and 71.3% at 10 years. A study examining autologous hematopoietic stem cell transplantation among patients with MS found long-lasting benefits (see Infographic below).
0 kommentar(er)
